Previous 10 | Next 10 |
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
Ultragenyx Pharmaceutical (NASDAQ: RARE ) preliminary full-year 2019 total revenue of $102M-$104M exceeds the average analyst estimate of $100.0M. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
Ultragenyx (NASDAQ: RARE ) and collaboration partner Kyowa Kirin ( OTCPK:KYKOF ) announce the filing of a supplemental marketing application in the U.S. seeking approval to use Crysvita (burosumab) to treat FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tum...
Preliminary 2019 total revenue is approximately $102 million to $104 million Preliminary 2019 Crysvita revenue to Ultragenyx of approximately $86 million to $88 million 2020 Crysvita revenue in Ultragenyx territories is expected to be in the range of $125 million to $140 million e...
NOVATO, Calif. and TOKYO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) today announced...
After disclosing the latest data for its gene therapy DTX301 in ornithine transcarbamylase (OTC) deficiency, Ultragenyx Pharmaceutical (NASDAQ: RARE) saw its shares gain 13.4% on Friday. Ultragenyx is a biotech stock focused on developing new treatments for rare dise...
Gainers: Sorrento Therapeutics (NASDAQ: SRNE ) +38% . More news on: Sorrento Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., Venus Concept Inc., Stocks on the move, Read more ...
Ultragenyx (NASDAQ: RARE ) announces positive results from cohort 3 and longer-term data from cohort 2 in an ongoing Phase 1/2 clinical trial evaluating gene therapy DTX301 in patients with ornithine transcarbamylase deficiency. More news on: Ultragenyx Pharmaceutical Inc., Healthcare ...
More uniform response in Cohort 3 with two confirmed responders and one potential responder New female responder in Cohort 2 for a total of three confirmed female responders across all cohorts Up to six responders across all nine patients dosed in study Prophylactic steroid c...
NOVATO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief E...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 ...
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empowe...
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfect...